company background image
CORT

Corcept Therapeutics NasdaqCM:CORT Stock Report

Last Price

US$27.97

Market Cap

US$3.0b

7D

-1.3%

1Y

36.2%

Updated

11 Aug, 2022

Data

Company Financials +
CORT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance6/6
Financial Health6/6
Dividends0/6

CORT Stock Overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.

Corcept Therapeutics Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Corcept Therapeutics
Historical stock prices
Current Share PriceUS$27.97
52 Week HighUS$29.93
52 Week LowUS$15.83
Beta0.51
1 Month Change6.59%
3 Month Change47.68%
1 Year Change36.17%
3 Year Change120.93%
5 Year Change91.57%
Change since IPO128.70%

Recent News & Updates

Aug 01

Corcept cut to Hold at Truist on balanced risk-reward setup

Citing a more balanced risk-reward profile following the recent outperformance of company shares, Truist downgraded commercial-stage pharma Corcept Therapeutics (NASDAQ:CORT) to Hold from Buy on Monday. The analyst Gregory Fraser highlights Corcept (CORT) shares registered over 45% gain this year compared to the ~13% decline in the S&P 500 and ~28% selloff in the S&P SPDR Biotech ETF (XBI). The analyst attributes the upsurge mainly to the growth potential of the company’s Cushing’s franchise and the longer-term prospects of its pipeline. Given the modest upside indicated in its $30 per share target, Fraser downgrades the stock as he sees a more balanced risk-reward set up for the stock. Truist’s view on Corcept (CORT) contrasts with that of Jefferies, which launched its coverage on the stock last week with a Buy recommendation citing the profitability of the company's Cushing Syndrome drug Korlym. Wall Street has remained bullish on Corcept (CORT) stock, with an average rating of Buy from analysts, while Seeking Alpha's quant system, which consistently beats the market, rated CORT as a Hold.

Shareholder Returns

CORTUS PharmaceuticalsUS Market
7D-1.3%-0.6%1.3%
1Y36.2%0.7%-11.7%

Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: CORT exceeded the US Market which returned -11.6% over the past year.

Price Volatility

Is CORT's price volatile compared to industry and market?
CORT volatility
CORT Average Weekly Movement6.1%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CORT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: CORT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998238Joseph Belanoffhttps://www.corcept.com

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.

Corcept Therapeutics Incorporated Fundamentals Summary

How do Corcept Therapeutics's earnings and revenue compare to its market cap?
CORT fundamental statistics
Market CapUS$3.00b
Earnings (TTM)US$112.72m
Revenue (TTM)US$392.03m

26.6x

P/E Ratio

7.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CORT income statement (TTM)
RevenueUS$392.03m
Cost of RevenueUS$5.20m
Gross ProfitUS$386.83m
Other ExpensesUS$274.11m
EarningsUS$112.72m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.05
Gross Margin98.67%
Net Profit Margin28.75%
Debt/Equity Ratio0%

How did CORT perform over the long term?

See historical performance and comparison